Name
Rejoyn (CT-152): A Prescription Digital Therapeutic for the Adjunctive Treatment of MDD Symptoms in Adults 22+
Description
Digital Therapeutics are a rapidly emerging class of clinically validated software-based interventions designed to treat a variety of conditions, including mental health disorders. This session will explore how an FDA-authorized digital therapeutic, Rejoyn, utilizes neuroplasticity to reduce symptoms of major depressive disorder (MDD)
Speakers
Pooja Raghani PsyD, MBI, Medical Science Liaison, Otsuka,
Thiago Queiroz PA-C, CAQ-Psych, Medical Science Liaison, Otsuka,
Content Level
All Audience
Tags
Innovations, Primary Care Behavioral Health Model, Psychiatry
Session Type
Poster
SIG or Committee
Primary Care Behavioral Health (PCBH)
Objective 1
Explain the role of digital therapeutics in mental health care, particularly how they leverage neuroplasticity to reduce symptoms of Major Depression Disorder
Objective 2
Distinguish the Different Digital Tools (health and wellness apps, patient monitoring and assessment tools, and digital therapeutics)
Objective 3
Identify opportunities for interdisciplinary collaboration in implementing digital therapeutics, enhancing patient-centered care through combined psychological, medical, and digital approaches.
Content Reference 1
Rothman B, Slomkowski M, Speier A, Rush AJ, Trivedi MH, Lawson E, Fahmy M, Carpenter D, Chen D, Forbes A Evaluating the Efficacy of a Digital Therapeutic (CT-152) as an Adjunct to Antidepressant Treatment in Adults With Major Depressive Disorder: Protocol for the MIRAI Remote Study JMIR Res Protoc 2024;13:e56960
Content Reference 2
Digital Therapeutics Alliance. June 2023. Accessed October 9, 2023. https://dtxalliance.org/wp-content/uploads/2023/06/Guidance-to-Industry-Classification-of-Digital-Health-Technologies-2023Jun05.pdf
Content Reference 3
Goldsack J, et al. November 10, 2019. Accessed February 7, 2023. https://www.dimesociety.org/digital-health-digital-medicine-digital-therapeutics-dtx-whats-the-difference